- Home
- IMCR vs SPHR Comparison
IMCR vs SPHR Comparison
Compare IMCR & SPHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- SPHR
- Stock Information
- Founded
- IMCR 2008
- SPHR 2020
- Country
- IMCR United Kingdom
- SPHR United States
- Employees
- IMCR N/A
- SPHR N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- SPHR Services-Misc. Amusement & Recreation
- Sector
- IMCR Health Care
- SPHR Consumer Discretionary
- Exchange
- IMCR Nasdaq
- SPHR Nasdaq
- Market Cap
- IMCR 1.5B
- SPHR 1.3B
- IPO Year
- IMCR 2021
- SPHR N/A
- Fundamental
- Price
- IMCR $31.34
- SPHR $38.56
- Analyst Decision
- IMCR Buy
- SPHR Buy
- Analyst Count
- IMCR 10
- SPHR 10
- Target Price
- IMCR $58.13
- SPHR $46.70
- AVG Volume (30 Days)
- IMCR 560.7K
- SPHR 527.8K
- Earning Date
- IMCR 08-07-2025
- SPHR 08-13-2025
- Dividend Yield
- IMCR N/A
- SPHR N/A
- EPS Growth
- IMCR N/A
- SPHR N/A
- EPS
- IMCR N/A
- SPHR N/A
- Revenue
- IMCR $333,581,000.00
- SPHR $1,031,650,000.00
- Revenue This Year
- IMCR $26.82
- SPHR $9.19
- Revenue Next Year
- IMCR $8.15
- SPHR $6.40
- P/E Ratio
- IMCR N/A
- SPHR N/A
- Revenue Growth
- IMCR 25.75
- SPHR 16.89
- 52 Week Low
- IMCR $23.15
- SPHR $23.89
- 52 Week High
- IMCR $41.54
- SPHR $50.88
- Technical
- Relative Strength Index (RSI)
- IMCR 40.28
- SPHR 57.23
- Support Level
- IMCR $35.10
- SPHR $37.94
- Resistance Level
- IMCR $37.56
- SPHR $40.06
- Average True Range (ATR)
- IMCR 1.74
- SPHR 1.18
- MACD
- IMCR -0.79
- SPHR -0.26
- Stochastic Oscillator
- IMCR 0.75
- SPHR 50.56
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About SPHR Sphere Entertainment Co.
Sphere Entertainment Co is a live entertainment and media company. The firm creates, writes, casts, produces, and tours shows and events. The group has two reportable segments which includeSphere and MSG Networks. Sphere is a next-generation entertainment medium, and MSG Networks operates two regional sports and entertainment networks, as well as a direct-to-consumer (DTC) and authenticated streaming product.